Frontier Dispatch: Deep Tech Conversations
The conversation covers the development of novel neurotherapeutics by Xylo, the motivation and impact behind the work, Xylo's unfair advantage, Zoma Labs' continuous glucose monitoring, their unfair advantage, and Currus Biologics' cell therapy for solid tumors. Hosted by Elaine Stead.
4 jaksot
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity Frontier Dispatch: Deep Tech Conversations-yhteisöön!